106PExperience of 22 patients with ROS mutated lung adenocarcinoma treated with crizotinib at a tertiary care center in India

Background: ROS1 hence became recognized as a distinct molecular target in NSCLC.Like ALK rearrangements ROS1 fusions are also found more in never smokers but define a distinct molecular subgroup with both rarely occurring together in same patient Crizotinib, a highly effective inhibitor of ROS1 kinase activity, is now FDA-approved for the treatment of patients with advanced ROS1-positive NSCLC .We report our experience in a tertiary cancer care centre in ROS-1 positive patients.

https://ift.tt/2D3aYS7